Tixagevimab and cilgavimab (sold as Evusheld) is a combination of two long-acting monoclonal antibodies used to prevent and lower the risk of severe COVID-19.
Tixagevimab and cilgavimab (sold as Evusheld) is a combination of two long-acting monoclonal antibodies used to prevent and lower the risk of severe COVID-19.
Image 1 of 1